The data monitoring committee (DMC) will be composed of clinical trial specialists, including a biostatistician, who are not associated with the study. The committee will meet at least twice a year, and all data obtained from the trial will be evaluated by the committee.
The DMC will review unblinded outcome data for safety and efficacy, and judge if there is evidence that either treatment is unsafe and the trial should be discontinued. The DMC will also advise the Trial Steering Committee of any evidence of unethical treatment or unacceptably serious adverse events.
The IBM Clinical Development Management System (IBM Corporation, Somers, New York), which is based on an EDC (Electronic Data Capture System), will be used to manage the data in this study.
Copyright and License information: The Author(s) ©2022 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Do you have any questions about this protocol?
Post your question to gather feedback from the community. We will also invite the authors of this
article to respond.